Top-News

Astria Therapeutics Aktie News

Aktie
WKN:  A3C2EY ISIN:  US04635X1028 US-Symbol:  ATXS Branche:  Biotechnologie Land:  USA
11,50 €
+0,3 €
+2,68%
04.12.25
Depot/Watchlist
Marktkapitalisierung *
1,93 Mrd. €
Streubesitz
2,14%
KGV
-5,35
Index-Zuordnung
-

Astria Therapeutics News

01.12.25 - PR Newswire
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights PR Newswire
01.12.25 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN PR Newswire
21.11.25 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-SPNS, PCH, ATXS, and RYN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-​SPNS, PCH, ATXS, and RYN PR Newswire
12.11.25 - PR Newswire
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights PR Newswire
06.11.25 - Businesswire
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-​changing therapies for allergic and immunologic diseases, today announced ...
31.10.25 - Businesswire
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-​changing therapies for allergic and immunologic diseases, today announced that ...
21.10.25 - PR Newswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders PR Newswire
14.10.25 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS) PR Newswire
14.10.25 - PR Newswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS, PCH, RYN on Behalf of Shareholders
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS, PCH, RYN on Behalf of Shareholders PR Newswire
14.10.25 - PR Newswire
Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders PR Newswire
09.10.25 - Businesswire
Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-​changing therapies for allergic and immunologic diseases, today announced that ...
03.10.25 - Businesswire
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-​changing therapies for allergic and immunologic diseases, today announced that ...
02.10.25 - Businesswire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-​changing therapies for allergic and immunologic diseases, granted stock options ...
02.10.25 - Businesswire
Astria Therapeutics rekrutiert nun HAE-Patienten in der Europäischen Union für die Phase-3-Studie ALPHA-ORBIT
Astria Therapeutics, Inc. (Nasdaq:ATXS), ein Biopharma-​Unternehmen mit Schwerpunkt auf der Entwicklung lebensverändernder Therapien für allergische und immunologische ...
02.10.25 - Businesswire
Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-​changing therapies for allergic and immunologic diseases, today announced that ...
17.09.25 - Businesswire
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-​changing therapies for allergic and immunologic diseases, today announced ...

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »